Daxas Advisory Committee Review May Look At Inclusion Criteria For Pivotal Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest's oral COPD drug will go before FDA's Pulmonary-Allergy Drugs Advisory Committee on April 7.
You may also be interested in...
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
On top of a class-wide Risk Evaluation and Mitigation Strategy for the long acting beta-2 adrenergic agonist class of asthma drugs, FDA is going to work through its Safe Use partners to monitor whether actual use adjusts based on the new safety measures
COPD: Disease Of The Future
Chronic obstructive pulmonary disease "is a disease that is increasingly becoming the new epidemic of our times," Forest Research Institute exec Ulo Palm said during Forest's recent late-stage pipeline review.
Forest Prepares For A Pair Of Launches, As Lexapro Generics Inch Closer
Forest expects SG&A spending to be heaviest in the fourth quarter, topping $325 million spent in the second quarter on upcoming launches.